Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL22P8 is one of multiple processed pseudogenes of the ribosomal protein L22 gene, which are dispersed throughout the human genome[2][4]. Pseudogenes such as RPL22P8 are non-functional copies of protein-coding genes and do not produce functional proteins. While RPL22 (the parental gene) encodes a component of the 60S ribosomal subunit involved in protein synthesis, RPL22P8 itself does not have a defined biological role, function, or relevance as a molecular drug target[2][4]. There is no evidence supporting its direct involvement in disease, nor is it known to interact with therapeutic compounds.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L22 pseudogene 8 (RPL22P8).